TRAPANI, DARIO
TRAPANI, DARIO
Dipartimento di Oncologia ed Emato-Oncologia
Extendeond Endocrine Therapy and Survival for Breast Cancer Subtypes in Premenopausal Patients
2026 C. Valenza, Y. Zheng, M. Milano, P.P.M. Berton Giachetti, D. Trapani, E. Giordano, L. Guidi, L. Boldrini, G. Castellano, J. Katrini, B. Malagutti, G. Antonarelli, J.D. Etessami, N. Bianco, F. Conforti, G.J. Kirkner, C. Sangalli, K.E. Dibble, N. Fusco, M. Colleoni, M.M. Regan, E. Munzone, G. Curigliano, A.H. Partridge
Inadequate ovarian function suppression and endocrine therapy manipulations in premenopausal patients with early breast cancer on adjuvant LHRH agonist and aromatase inhibitor: a cohort study
2026 C. Valenza, J.D. Etessami, M. Milano, N. Papadopoulos, M. Alvino, G. Antonarelli, N. Bianco, C. Sangalli, D. Trapani, G. Pravettoni, E. Omodeo Salè, R. Passerini, M. Colleoni, E. Munzone, G. Curigliano
Advancing oncology innovation under persistent constraints
2026 D. Trapani, G. Curigliano
Metastasis-directed thermal ablation in patients with metastatic breast cancer and visceral oligoprogression or oligopersistence: a cohort study
2026 N. Bianco, C. Valenza, M. Milano, R. Multinu, E. Battaiotto, M. Cavallone, G. Malvezzi, D. Trapani, P. Della Vigna, G. Bonomo, G.M. Varano, D. Maiettini, M.G. Pitoni, C. Sangalli, E. Munzone, G. Curigliano, M.A. Colleoni, F. Orsi
Invasive lobular and ductal breast cancers: a systematic review and metanalysis in association with BRCA1/2 mutation status
2026 G. Corso, C. Andreon, C. La Vecchia, E.I. Bottazzoli, G. Abruzzese, K. Favilla, O. Citterio, E. Spoldi, S. Di Silvestre, A.M. De Scalzi, A. Polizzi, E. Meduri, D. Trapani, L. Nicosia, F. Pesapane, D. Bossi, E. Brogi, S. Shen, R. Mukhtar, C. Criscitiello, P. Veronesi, S. Gandini, F. Magnoni, G. Curigliano
Pathological complete response with neoadjuvant pembrolizumab and chemotherapy in non-metastatic triple-negative inflammatory breast cancer
2026 F. Lynce, C. Valenza, S.M. Niman, F. Bertucci, M. Kai, S. Ryan, E. Troll, R.M. Layman, K.A. Fanucci, A. Giordano, A. Nasrazadani, F. Nakhlis, J. Bellon, L. Warren, C. Block, S. Schumer, A. Lucci, S. Krishnamurthy, D. Trapani, F. Lerebours, F. Dalenc, C. Levy, T. Petit, M. Leheurteur, T. Bachelot, O. Tredan, J.M. Ribeiro, B. Pistilli, P. Zagami, S. Ladoire, L. Lopez Almeida, C. Zemmour, L.A. Carey, S.M. Tolaney, V. Valero, G. Curigliano, M.M. Regan, A. Goncalves, W.A. Woodward
Genomic landscape, immune microenvironment and survival in male versus female breast cancer
2026 D. Trapani, S.K. Deshmukh, T. Samec, S. Wu, J. Xiu, P. Walker, D.L. Abravanel, P. Advani, P.M. Spanheimer, N.U. Lin, G. Curigliano, S.L. Graff, M. Lustberg, G.W. Sledge, S.M. Tolaney, J.P. Leone
A machine learning assay to predict disease recurrence in hormone receptor-positive breast cancer
2026 L. Boscolo Bielo, D. Trapani, P. Razavi, S. Chandarlapaty, Y. Zhan, G. Curigliano
Invasive lobular and ductal breast cancers: a systematic review and metanalysis in association with BRCA1/2 mutation status
2026 G. Corso, C. Andreon, C. La Vecchia, E.I. Bottazzoli, G. Abruzzese, K. Favilla, O. Citterio, E. Spoldi, S. Di Silvestre, A.M. De Scalzi, A. Polizzi, E. Meduri, D. Trapani, L. Nicosia, F. Pesapane, D. Bossi, E. Brogi, S. Shen, R. Mukhtar, C. Criscitiello, P. Veronesi, S. Gandini, F. Magnoni, G. Curigliano
Circulating tumor DNA: a biomarker for oncology drug development in phase I clinical trials?
2025 R. Asnaghi, R.M. Marsicano, V. Fuorivia, G. Malvezzi, J.D. Etessami, D. Izzo, C. Valenza, G. Curigliano, D. Trapani
ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0)
2025 N.I. Cherny, S.F. Oosting, U. Dafni, N.J. Latino, M. Galotti, P. Zygoura, G. Dimopoulou, T. Amaral, J. Barriuso, A. Calles, B. Kiesewetter, C. Gomez-Roca, B. Gyawali, M. Piccart, A. Passaro, F. Roitberg, N. Tarazona, D. Trapani, G. Curigliano, R. Wester, G. Zarkavelis, C. Zielinski, E.G.E. De Vries
Tearing down inequalities in the healthcare system across Europe: the BEACON project
2025 C. Koukoutzeli, G. Ferraris, V. Coppini, M.V. Ferrari, E. Fragale, D. Trapani, I. Minchella, R. Grasso, G. Curigliano, G. Pravettoni
Metastasis-directed stereotactic radiotherapy and systemic treatment continuation for patients with oligoprogressive metastatic breast cancer
2025 M. Milano, C. Valenza, A. Ferrari, S. Gandini, D. Trapani, C. Santoro, E. Battaiotto, A. Carnevale Schianca, E. Giordano, J. Katrini, G. Castellano, B. Taurelli Salimbeni, M.C. Leonardi, S. Dicuonzo, C. Criscitiello, N. Bianco, S. Dellapasqua, E. Munzone, G. Curigliano, M. Colleoni, B.A. Jereczek-Fossa
Molecular tumour board in gastrointestinal cancers
2025 L. Boscolo Bielo, E. Crimini, M. Repetto, M. Barberis, E. Battaiotto, J. Katrini, E. Martino, G. Gaudio, M. Lombardi, C. Zanzottera, G. Aurilio, C. Belli, Y. Zhan, V. Fuorivia, R.M. Marsicano, J.D. Etessami, P. Zagami, A. Marra, D. Trapani, B. Taurelli Salimbeni, C. Criscitiello, D. Ciardiello, B. Lavinia, L. Gervaso, C.A. Cella, F. Spada, M.G. Zampino, N. Fusco, N. Fazio, E. Guerini Rocco, G. Curigliano
Metronomic Chemotherapy in Breast Cancer as a Strategy to Deliver More Sustainable and Less Toxic Treatments: Time to Debunk the Myth?
2025 E. Battaiotto, S. D'Ambrosio, D. Trapani, G. Curigliano
Radioligand Therapy in Metastatic Breast Cancer: Harnessing Precision Oncology
2025 F. Giugliano, E. Giordano, L. Gilardi, B.T. Salimbeni, P. Zagami, A. Esposito, A. Marra, D. Trapani, P.P.M. Berton Giachetti, B. Malagutti, T. Henry, D. Deandreis, G. Curigliano, F. Ceci, C. Criscitiello
Mismatch repair (MMR) and microsatellite instability (MSI) phenotypes across solid tumors: A comprehensive cBioPortal study on prevalence and prognostic impact
2025 K. Venetis, C. Frascarelli, L.B. Bielo, G. Cursano, R. Adorisio, M. Ivanova, E. Mane, V. Peruzzo, A. Concardi, M. Negrelli, M. D'Ercole, F.M. Porta, Y. Zhan, A. Marra, D. Trapani, C. Criscitiello, G. Curigliano, E. Guerini-Rocco, N. Fusco
Innovative payloads for ADCs in cancer treatment: moving beyond the selective delivery of chemotherapy
2025 D. Izzo, L. Ascione, L. Guidi, R.M. Marsicano, C. Koukoutzeli, D. Trapani, G. Curigliano
Germline BRCA pathogenic variants and hematologic adverse events in patients with ovarian carcinoma receiving PARP inhibitors: a retrospective cohort study
2025 C. Valenza, E. Nicolò, M. Mongillo, D. Trapani, J. Katrini, L. Boldrini, L. Boscolo Bielo, G. Castellano, L. Guidi, G. Pellizzari, J. Villa, S. Derio, M. Lapresa, F. Gigli, G. Parma, E. Omodeo Salè, E. Derenzini, G. Curigliano, N. Colombo
Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer
2025 P.P.M. Berton Giachetti, S. Morganti, S. Gandini, F. Giudici, A. Marra, E. Nicolò, E. Zattarin, C. Corti, L. Boldrini, A. Verrazzo, C. Sposetti, M.G. Razeti, A. Carnevale Schianca, R. Scafetta, B. Taurelli Salimbeni, A. Esposito, P. Zagami, D. Trapani, B. Malagutti, R. Caputo, C. Vernieri, E. Munzone, S. Scagnoli, A. Botticelli, M. Lambertini, M. Giuliano, M. De Laurentiis, G. Viale, G. Bianchini, G. Curigliano, C. De Angelis, C. Criscitiello